BioCentury

BioCentury This Week

Science EN ↓ 385 episodes

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Author

BioCentury

Episodes

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up 22.03.2022 20:54

The importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketing strategy and what’s next among checkpoints in the clinic headline the latest BioCentury This Week podcast . BioCentury's editors also discuss why there’s still a lot of excitement regarding the IL-2 cancer pipeline despite last week’s setback for...

Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H 15.03.2022 21:46

Chinese immuno-oncology companies are changing how they interact with FDA as they seek approval of PD-1 programs. On this episode of BioCentury This Week, BioCentury’s editors discuss takeaways from a survey of CEOs and R&D heads developing PD-1 or PD-L1 inhibitors about what’s next for their programs. The team also previews translational data expected at next month’s meeting of the American A...

Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia 08.03.2022 22:23

War Pulls Biotech to Ukraine, Out of Russia: BioCentury's editors look at how the worsening crisis in Ukraine is affecting the global life sciences community, and discuss the challenges and tactics for removing Russian capital from biotech VC funds and the takeaways form a Guest Commentary by 4BIO Capital’s Dima Kuzmin that calls for a thoughtful approach to economic disengagement from Russia...

Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data 01.03.2022 22:12

Industry leaders have vowed to disengage with Russia until it stops its invasion of Ukraine and respects its neighbor’s sovereignty. What's the likely impact of their pledge and what are the implications of the crisis in Ukraine for biopharma companies around the globe? Plus: Assessing the latest cut of data for Intellia's pioneering in vivo CRISPR-Cas9 therapy and key takeaways from Was...

Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner 23.02.2022 22:39

Newly confirmed FDA commissioner Rob Califf will be prioritizing a proactive communications strategy, including combating misinformation about science, whilst guiding FDA through the pandemic and trying to keep the agency above Washington’s political fray. Plus, BioCentury’s editors discuss how late-stage investors are adapting to biotech’s bull market and Amgen’s application of its rapid developm...

Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting 15.02.2022 20:53

FDA and its advisory panel of oncology experts have repudiated the use of China-only data for regulatory submissions in the U.S. How will China's cancer companies adjust to this new regulatory environment? Plus, BioCentury's editors discuss the upcoming vote on Rob Califf, President Biden's nominee to become the next FDA commissioner, and the latest translational trends in cancer, i...

Ep. 101 - Of Biotech Bears, Pazdur & PDUFA 08.02.2022 28:41

Weathering the bear market. Oncology chief’s change in thinking on PD-1 therapies. Plus BioCentury’s 2021 innovative start-ups. This week’s podcast is sponsored by ICON . Reach us by sending a text

Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns 01.02.2022 26:46

This week’s podcast is sponsored by ICON . Reach us by sending a text

Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK 25.01.2022 26:13

BioCentury’s new in-depth conversational series launches with Scott Gottlieb as debut guest. This week’s podcast is sponsored by ICON . Reach us by sending a text

Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS 19.01.2022 23:38

Part two of BioCentury’s 2022 Financial Markets Preview, access to Alzheimer’s mAbs, and translational highlights from the Distillery. This week’s podcast is sponsored by ICON . Reach us by sending a text

Ep. 97 - Buysiders' Picks, plus JPM22 roundup 11.01.2022 27:38

Reach us by sending a text

Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap 21.12.2021 23:19

Reach us by sending a text

Ep. 95 - ASH's New Targets, Avistone & Washington Update 14.12.2021 19:36

Reach us by sending a text

Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery 07.12.2021 22:45

Reach us by sending a text

Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases 30.11.2021 19:54

Reach us by sending a text

Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights 22.11.2021 23:13

Reach us by sending a text